Shattuck Labs shares are trading lower after the company announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154.
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs shares fell after announcing the discontinuation of its SL-172154 clinical program due to modest results. The company will focus on developing SL-325 for inflammatory bowel disease, with an IND filing expected in Q3 2025. Restructuring is expected to extend cash runway into 2027.
October 01, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Shattuck Labs shares declined after the company announced it would discontinue its SL-172154 program due to modest clinical results. The focus will shift to SL-325, targeting inflammatory bowel disease, with an IND filing expected in Q3 2025. Restructuring is anticipated to extend the cash runway into 2027.
The discontinuation of the SL-172154 program due to modest results negatively impacts investor sentiment, leading to a decline in share price. The shift in focus to SL-325 and the restructuring plan are long-term strategies, but the immediate impact is negative due to the halted program.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100